ATE74272T1 - Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie. - Google Patents

Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.

Info

Publication number
ATE74272T1
ATE74272T1 AT87100809T AT87100809T ATE74272T1 AT E74272 T1 ATE74272 T1 AT E74272T1 AT 87100809 T AT87100809 T AT 87100809T AT 87100809 T AT87100809 T AT 87100809T AT E74272 T1 ATE74272 T1 AT E74272T1
Authority
AT
Austria
Prior art keywords
human
treatment
pharmaceutical agent
csf
leukemia
Prior art date
Application number
AT87100809T
Other languages
English (en)
Inventor
Masahiko Tamura
Kunihiro Hattori
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE74272T1 publication Critical patent/ATE74272T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT87100809T 1986-01-22 1987-01-21 Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie. ATE74272T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1028186 1986-01-22
EP87100809A EP0231819B1 (de) 1986-01-22 1987-01-21 Pharmazeutischer Stoff für die Behandlung von myelogener Leukämie

Publications (1)

Publication Number Publication Date
ATE74272T1 true ATE74272T1 (de) 1992-04-15

Family

ID=11745925

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87100809T ATE74272T1 (de) 1986-01-22 1987-01-21 Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.

Country Status (5)

Country Link
EP (1) EP0231819B1 (de)
AT (1) ATE74272T1 (de)
CA (1) CA1297005C (de)
DE (1) DE3777845D1 (de)
ES (1) ES2036530T3 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE19860801A1 (de) * 1998-12-30 2000-07-06 Rhein Biotech Proz & Prod Gmbh Rekombinanter Wachstumsfaktor mit der biologischen Aktivität eines G-CSF (Granulocyte Colony Stimulating Factor)
AU6875900A (en) 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
KR100408429B1 (ko) * 2000-01-24 2003-12-06 한미약품 주식회사 유즙 중에 인간 과립구 콜로니 자극인자를 생산하는형질전환 흑염소
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
EP2277910A1 (de) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin Fusionsproteine
EP2426139B1 (de) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4-Antagonisten und Verwendung davon
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
CA2673719C (en) 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
CN111375066B (zh) 2015-07-16 2023-04-25 百欧肯治疗有限公司 治疗癌症的组合物及方法
MX2018010125A (es) 2016-02-23 2019-03-28 Biolinerx Ltd Procedimientos de tratamiento de leucemia mieloide aguda.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2908627A1 (de) * 1979-03-06 1980-09-11 Bayer Ag Neue trishydroxyalkylheterocyclen
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) * 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.

Also Published As

Publication number Publication date
EP0231819B1 (de) 1992-04-01
DE3777845D1 (de) 1992-05-07
ES2036530T3 (es) 1993-06-01
CA1297005C (en) 1992-03-10
EP0231819A3 (en) 1989-03-08
EP0231819A2 (de) 1987-08-12

Similar Documents

Publication Publication Date Title
ATE74272T1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
ATE71662T1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
DE3771509D1 (de) Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
DE3684732D1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
PT82457A (en) Process for the preparation of pharmaceutical compound with base in phosphonil-methoxy-alkyl-adenines with antiviral activity
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
IL87621A0 (en) Conjugates of cytokines with immunoglobulins,their preparation and pharmaceutical compositions containing them
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
DE69007744D1 (de) Verwendung von Interleukin 2 zur Behandlung von Leukämien.
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE69034076D1 (de) Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie
DE3771584D1 (de) Zusammensetzungen und anwendung von interleukin-2 und/oder interferon-beta und des tumor-necrosis-faktors fuer eine kombinationstherapie oder zur herstellung von arzneimitteln oder formulierungen.
DE3861494D1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
ZA873743B (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
DE3750248D1 (de) Zubereitung und Behandlung der Haut mit Human-Leukocyten-Interferon.
KR900700156A (ko) 개선된 방사선 치료법
ZA9010409B (en) Utilisation of a polypeptide with human 2 interleukine activity in the preparation of a pharmaceutical composition for the treatment of epithelial malignant tumours
Seki et al. Induction of eosinophil chemotactic factor production from human peripheral blood mononuclear cells by solubilized BALL-1, a B cell lymphoma line
DE69005837D1 (de) Verwendung bestimmter gamma-Interferone zur Behandlung von Krebs des Ovars.
ATE65404T1 (de) Zusammensetzungen und anwendung von interleukin-2 und/oder interferon-beta und des tumor-necrosis- faktors fuer eine kombinationstherapie oder zur herstellung von arzneimitteln oder formulierungen.
GR950100316A (el) Φαρμακευτικο παρασκευασμα βασιζομενο σε αιωρημα εμβρυικων κυτταρων με δραση ανοσοποιητικης υποκαταστασης και μεθοδος θεραπειας του συνδρομου της επικτητης μολυνσης ανοσοποιητικης ανεπαρκειας (hiv) με τη χρηση αυτου του παρασκευασματος.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time